TABLE 1.
Patient characteristics at the time of pvDNA V3 genotyping
| Characteristica | Value |
|---|---|
| No. of patients | 55 |
| Male (no. [%]) | 38 (69.1) |
| Age (median [IQR]) (yr) | 50 (43–55) |
| Nationality (no. [%]) | |
| Italian | 44 (80.0) |
| African | 6 (10.9) |
| Other | 5 (9.1) |
| HIV exposure (no. [%]) | |
| Heterosexual sex | 17 (30.9) |
| MSM | 12 (21.8) |
| IDU | 6 (10.9) |
| Unknown or other | 20 (36.4) |
| Subtype (no. [%]) | |
| B | 43 (78.2) |
| Non-Bb | 12 (21.8) |
| CD4+ cell count (median [IQR]) (cells/mm3) | |
| At RNA sequencing | 375 (233–615) |
| At DNA sequencing | 375 (262–714) |
| Past drug treatment (no. [%]) | |
| NRTI | 53 (96) |
| NNRTI | 29 (53) |
| PI | 51 (93) |
| INI | 17 (31) |
| Enfuvirtide | 3 (5.4) |
| Maraviroc | 7 (12.7) |
| Treatment status (no. [%]) | |
| Receiving treatment | 48 (87.3) |
| In treatment interruption | 7 (12.7) |
| Current drug treatment (no. [%])c | |
| NRTI | 42 (76.4) |
| NNRTI | 13 (24) |
| PI | 31 (56.4) |
| INI | 10 (18) |
| Enfuvirtide | 5 (9) |
| Maraviroc | 5 (9) |
a
MSM, men having sex with men; IDU, injection drug use; NRTI, nucleotide reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INI, integrase inhibitor.
b
C (n = 3), BF (n = 3), F1 (n = 2), G (n = 2), BC (n = 1), or CRF06_cpx (n = 1).
c
Six (10.9%) of 55 patients were undergoing different treatments at the time of RNA genotyping versus the time of pvDNA genotyping.